Decline in no-authorized generic deals, FTC reports
Fewer patent settlements involve agreements by branded drug companies to stay out of the generic marketplace, according to a Federal Trade Commission report....
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: